Real-world outcomes for transcatheter aortic valve replacement (TAVR) patients are likely similar to those observed in randomized controlled trials (RCTs), despite some key differences in important baseline characteristics between those treated in trial and clinic, researchers comparing U.S. CoreValve trial results with Medicare data said.